Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies
The dependence of tumor growth and metastasis on blood vessels makes tumor angiogenesis a rational target for therapy. Strategies have been pursued to inhibit neovascularization and to destroy existing tumor vessels, or both. These include direct targeting of endothelial cells, and indirect targetin...
Main Authors: | Cristina Rabascio, Francesco Bertolini |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2010-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/2/2/1027/ |
Similar Items
-
Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine
by: Chao Mei, et al.
Published: (2023-03-01) -
CYR61—An angiogenic biomarker to early predict the impaired healing in diaphyseal tibial fractures
by: Sabir Ali, et al.
Published: (2017-07-01) -
Trends and Challenges in Tumor Anti-Angiogenic Therapies
by: József Jászai, et al.
Published: (2019-09-01) -
Vascular co-option in resistance to anti-angiogenic therapy
by: Domenico Ribatti, et al.
Published: (2023-12-01) -
Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma
by: Ashley B. Zhang, et al.
Published: (2023-01-01)